Sofinnova Investments, Inc. Exelixis, Inc. Transaction History

Sofinnova Investments, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$18.17 - $20.48 $31.4 Million - $35.4 Million	1,729,495 Added 208.06%	2,560,738 $48.9 Million
Q1 2023 May 11, 2023	BUY	$16.3 - $19.41 $13.5 Million - $16.1 Million	831,243 New	831,243 $16.1 Million
Q4 2021 Feb 14, 2022	SELL	$15.84 - $21.88 $7.74 Million - $10.7 Million	-488,414 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$16.3 - $21.14 $9.64 Million - $12.5 Million	-591,267 Reduced 54.76%	488,414 $10.3 Million
Q2 2021 Aug 16, 2021	BUY	$17.95 - $25.56 $4.32 Million - $6.15 Million	240,500 Added 28.66%	1,079,681 $19.7 Million
Q1 2021 May 14, 2021	BUY	$20.53 - $25.22 $17.2 Million - $21.2 Million	839,181 New	839,181 $19 Million
Q4 2018 Feb 14, 2019	SELL	$13.65 - $21.8 $5.51 Million - $8.8 Million	-403,594 Closed	0 $0
Q3 2018 Nov 15, 2018	BUY	$15.87 - $22.4 $6.41 Million - $9.04 Million	403,594 New	403,594 $7.15 Million

503

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.2B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Sofinnova Investments, Inc., based on Form 13F filings with the SEC.

Stay updated on Sofinnova Investments, Inc. with notifications on news.